High levels of a constitutively active Foxa2 protein (Foxa2T156A), but not the wild-type protein, can decrease liver steatosis [3], suggesting that Foxa2 could be a pharmacological target for the treatment of NAFL and for improving liver insulin sensitivity [36]. This evidence concerns the gene INS and fatty liver disease.